| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website https://www.journalmc.org |
Case Report
Volume 13, Number 5, May 2022, pages 240-243
Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series
Table
| Case series | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| MMR: mismatch repair expression; PD-L1: programmed death-ligand 1. | |||
| Age on diagnosis (years) | 51 | 63 | 35 |
| Clinical staging | Borderline resectable | Initially locally advanced and recurrence with metastatic | Metastatic |
| MMR status | Deficient MMR expression | Intact MMR expression | Intact MMR expression |
| Tumor mutational burden status | |||
| PD-L1 status | Not tested | PD-L1 positive | PD-L1 positive |
| Treatment | Neoadjuvant chemotherapy and surgical resection | Neoadjuvant chemotherapy and surgical resection followed by chemoradiation | Three different regiments of chemotherapy due to progression |
| Use of pembrolizumab | Single maintenance therapy | Combine with olaparib as maintenance therapy | Combine with chemotherapy and olaparib |
| Follow-up | 4 years | 3 years | 8 months |